Cargando…
Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
Cell therapy is a distinguished targeted immunotherapy with great potential to treat solid tumors in the new era of cancer treatment. Cell therapy products include genetically engineered cell products and non-genetically engineered cell products. Several recent cell therapies, especially chimeric an...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339623/ https://www.ncbi.nlm.nih.gov/pubmed/35924243 http://dx.doi.org/10.3389/fimmu.2022.896685 |
_version_ | 1784760208100163584 |
---|---|
author | Chen, Kun Wang, Shuhang Qi, Dan Ma, Peiwen Fang, Yuan Jiang, Ning Wu, Erxi Li, Ning |
author_facet | Chen, Kun Wang, Shuhang Qi, Dan Ma, Peiwen Fang, Yuan Jiang, Ning Wu, Erxi Li, Ning |
author_sort | Chen, Kun |
collection | PubMed |
description | Cell therapy is a distinguished targeted immunotherapy with great potential to treat solid tumors in the new era of cancer treatment. Cell therapy products include genetically engineered cell products and non-genetically engineered cell products. Several recent cell therapies, especially chimeric antigen receptor (CAR)-T cell therapies, have been approved as novel treatment strategies for cancer. Many clinical trials on cell therapies, in the form of cell therapy alone or in combination with other treatments, in solid tumors, have been conducted or ongoing. However, there are still challenges since adverse events and the limited efficacy of cell therapies have also been observed. Here, we concisely summarize the clinical milestones of the conducted and ongoing clinical trials of cell therapy, introduce the evolution of CARs, discuss the challenges and limitations of these therapeutic modalities taking CAR-T as the main focus, and analyze the disparities in the regulatory policies in different countries. |
format | Online Article Text |
id | pubmed-9339623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93396232022-08-02 Clinical Investigations of CAR-T Cell Therapy for Solid Tumors Chen, Kun Wang, Shuhang Qi, Dan Ma, Peiwen Fang, Yuan Jiang, Ning Wu, Erxi Li, Ning Front Immunol Immunology Cell therapy is a distinguished targeted immunotherapy with great potential to treat solid tumors in the new era of cancer treatment. Cell therapy products include genetically engineered cell products and non-genetically engineered cell products. Several recent cell therapies, especially chimeric antigen receptor (CAR)-T cell therapies, have been approved as novel treatment strategies for cancer. Many clinical trials on cell therapies, in the form of cell therapy alone or in combination with other treatments, in solid tumors, have been conducted or ongoing. However, there are still challenges since adverse events and the limited efficacy of cell therapies have also been observed. Here, we concisely summarize the clinical milestones of the conducted and ongoing clinical trials of cell therapy, introduce the evolution of CARs, discuss the challenges and limitations of these therapeutic modalities taking CAR-T as the main focus, and analyze the disparities in the regulatory policies in different countries. Frontiers Media S.A. 2022-07-18 /pmc/articles/PMC9339623/ /pubmed/35924243 http://dx.doi.org/10.3389/fimmu.2022.896685 Text en Copyright © 2022 Chen, Wang, Qi, Ma, Fang, Jiang, Wu and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Chen, Kun Wang, Shuhang Qi, Dan Ma, Peiwen Fang, Yuan Jiang, Ning Wu, Erxi Li, Ning Clinical Investigations of CAR-T Cell Therapy for Solid Tumors |
title | Clinical Investigations of CAR-T Cell Therapy for Solid Tumors |
title_full | Clinical Investigations of CAR-T Cell Therapy for Solid Tumors |
title_fullStr | Clinical Investigations of CAR-T Cell Therapy for Solid Tumors |
title_full_unstemmed | Clinical Investigations of CAR-T Cell Therapy for Solid Tumors |
title_short | Clinical Investigations of CAR-T Cell Therapy for Solid Tumors |
title_sort | clinical investigations of car-t cell therapy for solid tumors |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339623/ https://www.ncbi.nlm.nih.gov/pubmed/35924243 http://dx.doi.org/10.3389/fimmu.2022.896685 |
work_keys_str_mv | AT chenkun clinicalinvestigationsofcartcelltherapyforsolidtumors AT wangshuhang clinicalinvestigationsofcartcelltherapyforsolidtumors AT qidan clinicalinvestigationsofcartcelltherapyforsolidtumors AT mapeiwen clinicalinvestigationsofcartcelltherapyforsolidtumors AT fangyuan clinicalinvestigationsofcartcelltherapyforsolidtumors AT jiangning clinicalinvestigationsofcartcelltherapyforsolidtumors AT wuerxi clinicalinvestigationsofcartcelltherapyforsolidtumors AT lining clinicalinvestigationsofcartcelltherapyforsolidtumors |